RV
RVMD
Revolution Medicines, Inc.
$148.49
-0.50%
$31.6B
No data for this timeframe.
Vol
Market Cap$31.6B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (96%)
Inst. Holders8 funds
Inst. Value$2.5B
Inst. Activity3 buys / 2 sells
Insider Activity0B / 12S
Insider Net $-$21.6M
Reddit Sentiment68° Warm
SEC Reports2
Press Releases9
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001628171·Prev Close $149.23
Recent Activity
Jun 9, 2026
short_volume
Short Volume: RVMD — 61.4% short (0.5M / 0.8M)
Short: 509,106 | Exempt: 5,828 | TRF Vol: 828,660 | Short Ratio: 61.4% | Off-exchange volume (dark p
May 31, 2026
Press
Revolution Medicines reported overwhelmingly positive Phase 3 data for daraxonrasib in metastatic pancreatic cancer, sho
Impact 8/10
May 26, 2026
Insider
Mancini Anthony sold 3,121 shares
See Remarks @ $33.62 ($104.9K)
May 26, 2026
Insider
Mancini Anthony sold 3,121 shares
See Remarks @ $0.00 ($0.00)
May 26, 2026
Insider
Mancini Anthony sold 700 shares
See Remarks @ $153.30 ($107.3K)
May 6, 2026
Press
Revolution Medicines announced that Phase 1/2 data for daraxonrasib in RAS-mutant pancreatic cancer were published in NE
Impact 8/10
Mar 27, 2026
SEC
Anthony Mancini, an insider at Revolution Medicines, exercised options for 74,900 shares and sold 1,800 shares on the op
CLUSTER — Impact 4/10
Feb 25, 2026
SEC
Revolution Medicines reported its 2025 financial results, highlighting a $1.1 billion net loss on $987.3 million in R&D
8-K — Impact 5/10
Price Targets
$187.29
+25.2% upside
Strong Buy
Current $149.55
Low $151.00
Median $183.00
High $263.00
21 analysts
$151.00
$263.00
Analyst Ratings
11Strong Buy
15Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 2, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| Jun 1, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jun 1, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| May 22, 2026 | Bernstein | INITIATE | Market Perform |
| May 7, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-2.03 ▼ -2.0% | $-2.19 — $-1.89 | -55% YoY | 18 |
| Next Q | $-1.97 ▼ -0.7% | $-2.23 — $-1.68 | -22% YoY | 18 |
| Current FY | $-8.01 ▼ -0.5% | $-8.81 — $-7.20 | -35% YoY | 19 |
| Next FY | $-5.70 ▼ -3.6% | $-10.74 — $0.96 | 29% YoY | 17 |
Latest Reports
BULLISH
Press
8/10
Revolution Medicines reported overwhelmingly positive Phase 3 data for daraxonrasib in metastatic pancreatic cancer, sho
May 31, 2026
NEUTRAL
CLUSTER
4/10
Anthony Mancini, an insider at Revolution Medicines, exercised options for 74,900 shares and sold 1,800 shares on the op
Mar 27, 2026
NEUTRAL
8-K
5/10
Revolution Medicines reported its 2025 financial results, highlighting a $1.1 billion net loss on $987.3 million in R&D
Feb 25, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.3B | — |
| FMR LLC | $684.0M | — |
| NORGES BANK | $195.6M | NEW |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $134.1M | NEW |
| BANK OF AMERICA CORP | $70.1M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 26, 2026 | Mancini Anthony | M | $104.9K |
| May 26, 2026 | Mancini Anthony | M | $0.00 |
| May 26, 2026 | Mancini Anthony | SELL | $107.3K |
| Apr 27, 2026 | Mancini Anthony | M | $104.9K |
| Apr 27, 2026 | Mancini Anthony | SELL | $220.0K |
Reddit Sentiment
68°
Warm
Bearish
Neutral
Bullish
8 institutional holders with $2.5B total value (31,419,775 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, NORGES. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 16,719,886 | $1.3B | 53.2% | — |
| 2 | FMR LLC | 8,587,981 | $684.0M | 27.3% | — |
| 3 | NORGES BANK | 2,455,347 | $195.6M | 7.8% | NEW |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,683,729 | $134.1M | 5.4% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 879,845 | $70.1M | 2.8% | ADD +30.7% |
| 6 | MORGAN STANLEY | 651,732 | $51.9M | 2.1% | TRIM -54.6% |
| 7 | TWO SIGMA INVESTMENTS, LP | 421,735 | $33.6M | 1.3% | DOUBLED +4530.9% |
| 8 | WELLS FARGO & COMPANY/MN | 19,520 | $1.6M | 0.1% | ADD +27.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 2,455,347 | — | $195.6M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 1,434,642 | 651,732 | -54.6% | $51.9M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 9,107 | 421,735 | +4530.9% | $33.6M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 15,320 | 19,520 | +27.4% | $1.6M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 253,104 | 0 | -100.0% | $0.00 | 2025-Q4 |
| MORGAN STANLEY | ADD | 1,051,037 | 1,434,642 | +36.5% | $67.0M | 2025-Q3 |
| UBS Group AG | DOUBLED | 514,753 | 1,088,965 | +111.6% | $50.9M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 576,683 | 753,867 | +30.7% | $35.2M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 9,107 | — | $425.3K | 2025-Q3 |
| NORGES BANK | EXIT | 1,701,111 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | NEW | — | 1,701,111 | — | $62.6M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 446,562 | 576,683 | +29.1% | $21.2M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 142,804 | 243,504 | +70.5% | $9.0M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 92,470 | 14,040 | -84.8% | $516.5K | 2025-Q2 |
| MORGAN STANLEY | ADD | 858,278 | 1,255,687 | +46.3% | $44.4M | 2025-Q1 |
| UBS Group AG | ADD | 299,783 | 482,107 | +60.8% | $17.0M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 142,804 | — | $5.0M | 2025-Q1 |
| NORGES BANK | EXIT | 1,742,039 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | ADD | 652,818 | 858,278 | +31.5% | $37.5M | 2024-Q4 |
| UBS Group AG | ADD | 193,079 | 299,783 | +55.3% | $13.1M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 58,172 | 88,327 | +51.8% | $3.9M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,763,117 | — | $80.0M | 2024-Q3 |
| MORGAN STANLEY | TRIM | 995,489 | 652,818 | -34.4% | $29.6M | 2024-Q3 |
9 unique insiders with 12 transactions. Net insider value: -$21.6M ($0.00 bought, $21.6M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 26, 2026 | Mancini Anthony | See Remarks | M | 3,121 | $33.62 | $104.9K |
| May 26, 2026 | Mancini Anthony | See Remarks | M | 3,121 | $0.00 | $0.00 |
| May 26, 2026 | Mancini Anthony | See Remarks | SELL | 700 | $153.30 | $107.3K |
| Apr 27, 2026 | Mancini Anthony | See Remarks | M | 3,120 | $33.62 | $104.9K |
| Apr 27, 2026 | Mancini Anthony | See Remarks | SELL | 1,671 | $131.66 | $220.0K |
| Apr 27, 2026 | Mancini Anthony | See Remarks | M | 3,120 | $0.00 | $0.00 |
| Apr 15, 2026 | GOLDSMITH MARK A | See Remarks | M | 23,244 | $4.09 | $95.1K |
| Apr 15, 2026 | GOLDSMITH MARK A | See Remarks | SELL | 120,000 | $150.09 | $18.0M |
| Apr 15, 2026 | GOLDSMITH MARK A | See Remarks | M | 23,244 | $0.00 | $0.00 |
| Mar 25, 2026 | Mancini Anthony | See Remarks | M | 37,450 | $33.62 | $1.3M |
| Mar 25, 2026 | Mancini Anthony | See Remarks | SELL | 1,800 | $93.22 | $167.8K |
| Mar 25, 2026 | Mancini Anthony | See Remarks | M | 37,450 | $0.00 | $0.00 |
| Mar 19, 2026 | Cislini Jeff | General Counsel | SELL | 1,163 | $97.44 | $113.3K |
| Mar 17, 2026 | Wang Xiaolin | See Remarks | SELL | 2,010 | $99.48 | $200.0K |
| Mar 17, 2026 | Anders Jack | Chief Financial Officer | SELL | 2,753 | $99.48 | $273.9K |
| Mar 17, 2026 | Cislini Jeff | General Counsel | SELL | 1,795 | $99.48 | $178.6K |
| Mar 17, 2026 | GOLDSMITH MARK A | See Remarks | SELL | 12,871 | $99.48 | $1.3M |
| Mar 17, 2026 | Horn Margaret A | Chief Operating Officer | SELL | 4,583 | $99.48 | $455.9K |
| Mar 17, 2026 | Kelsey Stephen Michael | See Remarks | SELL | 4,302 | $99.48 | $428.0K |
| Mar 17, 2026 | Wei Lin | Chief Medical Officer | SELL | 2,073 | $99.48 | $206.2K |
| Mar 4, 2026 | ANDERSON ELIZABETH M | Director | G | 15,000 | $0.00 | $0.00 |
| Mar 2, 2026 | GOLDSMITH MARK A | See Remarks | M | 30,000 | $4.09 | $122.7K |
| Mar 2, 2026 | GOLDSMITH MARK A | See Remarks | M | 30,000 | $0.00 | $0.00 |
| Mar 1, 2026 | GOLDSMITH MARK A | See Remarks | A | 57,100 | $0.00 | $0.00 |
| Mar 1, 2026 | GOLDSMITH MARK A | See Remarks | A | 128,600 | $0.00 | $0.00 |
| Mar 1, 2026 | Cislini Jeff | General Counsel | A | 32,500 | $0.00 | $0.00 |
| Mar 1, 2026 | Anders Jack | Chief Financial Officer | A | 45,400 | $0.00 | $0.00 |
| Mar 1, 2026 | Horn Margaret A | Chief Operating Officer | A | 21,100 | $0.00 | $0.00 |
| Mar 1, 2026 | Anders Jack | Chief Financial Officer | A | 20,200 | $0.00 | $0.00 |
| Mar 1, 2026 | Kelsey Stephen Michael | See Remarks | A | 21,100 | $0.00 | $0.00 |
| Mar 1, 2026 | Wang Xiaolin | See Remarks | A | 15,100 | $0.00 | $0.00 |
| Mar 1, 2026 | Wang Xiaolin | See Remarks | A | 34,000 | $0.00 | $0.00 |
| Mar 1, 2026 | Wei Lin | Chief Medical Officer | A | 15,100 | $0.00 | $0.00 |
| Mar 1, 2026 | Wei Lin | Chief Medical Officer | A | 34,000 | $0.00 | $0.00 |
| Mar 1, 2026 | Kelsey Stephen Michael | See Remarks | A | 47,600 | $0.00 | $0.00 |
| Mar 1, 2026 | Horn Margaret A | Chief Operating Officer | A | 47,600 | $0.00 | $0.00 |
| Mar 1, 2026 | Cislini Jeff | General Counsel | A | 14,500 | $0.00 | $0.00 |
| Feb 6, 2026 | GOLDSMITH MARK A | See Remarks | M | 24,010 | $0.00 | $0.00 |
| Feb 6, 2026 | GOLDSMITH MARK A | See Remarks | M | 24,010 | $0.5400 | $13.0K |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.5/10.
BULLISH
8/10
Revolution Medicines reported overwhelmingly positive Phase 3 data for daraxonrasib in metastatic pa
May 31, 2026
BULLISH
8/10
Revolution Medicines announced that Phase 1/2 data for daraxonrasib in RAS-mutant pancreatic cancer
May 6, 2026
BULLISH
8/10
Revolution Medicines announced updated Phase 1/2 data for daraxonrasib in previously untreated metas
Apr 21, 2026
BULLISH
7/10
Revolution Medicines announced preclinical data for RM-055, a novel oral catalytic RAS(ON) inhibitor
Apr 21, 2026
BULLISH
8/10
Revolution Medicines announced that detailed results from its Phase 3 RASolute 302 trial of daraxonr
Apr 21, 2026
BULLISH
8/10
Revolution Medicines announced updated Phase 1 data for zoldonrasib in KRAS G12D non-small cell lung
Apr 19, 2026
BEARISH
7/10
Revolution Medicines raised approximately $2.225 billion through a concurrent public offering of com
Apr 17, 2026
BEARISH
7/10
Revolution Medicines announced the pricing of concurrent public offerings: 10.56M shares of common s
Apr 15, 2026
BEARISH
7/10
Revolution Medicines announced two concurrent capital raises: a $750 million common stock offering a
Apr 13, 2026
Current analyst consensus: Strong Buy (96% buy). Based on 27 analysts: 11 strong buy, 15 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$187.29 mean target
+25.2% upside
Strong Buy (1.29)
$151.00 Low
$263.00 High
| Metric | Value |
|---|---|
| Current Price | $149.55 |
| Target Low | $151.00 |
| Target Mean | $187.29 |
| Target Median | $183.00 |
| Target High | $263.00 |
| # Analysts | 21 |
| Recommendation | Strong Buy (1.29) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-2.03 | $-2.19 | $-1.89 | -54.9% | -2.0% | 1↑ 14↓ | $0.0B | 0.0% | 18 |
| Next Q 2026-09-30 |
$-1.97 | $-2.23 | $-1.68 | -22.4% | -0.7% | 8↑ 7↓ | $0.0B | 0.0% | 18 |
| Current FY 2026-12-31 |
$-8.01 | $-8.81 | $-7.20 | -34.5% | -0.5% | 2↑ 16↓ | $0.1B | 0.0% | 19 |
| Next FY 2027-12-31 |
$-5.70 | $-10.74 | $0.96 | 28.8% | -3.6% | 7↑ 8↓ | $0.8B | 706.4% | 17 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-2.029 | |
| 7d ago | $-2.028 | -0.001 |
| 30d ago | $-1.990 | -0.039 |
| 60d ago | $-1.914 | -0.115 |
| 90d ago | $-1.891 | -0.137 |
14 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 2, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jun 1, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jun 1, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| May 22, 2026 | Bernstein | INITIATE | — | Market Perform |
| May 7, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 7, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| May 7, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| May 7, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| May 7, 2026 | Needham | MAINTAIN | Buy | Buy |
| Apr 22, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Apr 22, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 20, 2026 | Stifel | REITERATE | Buy | Buy |
| Apr 20, 2026 | Needham | MAINTAIN | Buy | Buy |
| Apr 14, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Apr 14, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 14, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Apr 14, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Apr 14, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Apr 14, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 13, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Apr 13, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Feb 26, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Feb 26, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 26, 2026 | Needham | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Jan 27, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Jan 22, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Jan 21, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 20, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Jan 13, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Jan 9, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 11 | 15 | 1 | 0 | 0 | 96% | |
| May 1, 2026 | 11 | 15 | 1 | 0 | 0 | 96% | |
| Apr 1, 2026 | 11 | 15 | 1 | 0 | 0 | 96% | |
| Mar 1, 2026 | 11 | 15 | 1 | 0 | 0 | 96% | |
| Feb 1, 2026 | 11 | 15 | 1 | 0 | 0 | 96% | |
| Jan 1, 2026 | 11 | 15 | 1 | 0 | 0 | 96% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
68°
Warm
Bearish
Neutral
Bullish
7 mentions
4 bullish
0 bearish
7 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 7, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 7, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 7, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 12, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Apr 15, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Stock that might jump Monday: RVMD
▲ 1
💬 0
⚡ 0.5
RVMD made a medical BREAKTHROUGH that now has limited availability in hospitals... but how are this company's financials?
▲ 1
💬 0
⚡ 0.5
RVMD ran from $34 to $144 before Phase 3 results drop these summer - is the risk reward still there?
▲ 1
💬 0
⚡ 0.4
RVMD/RVMDW Question
▲ 1
💬 0
⚡ 0.5
Tips for researching startups?
▲ 1
💬 0
⚡ 0.5
Too late for RVMD?
▲ 1
💬 0
⚡ 0.5
Jun 9, 2026
short_volume
Short Volume: RVMD — 61.4% short (0.5M / 0.8M)
Short: 509,106 | Exempt: 5,828 | TRF Vol: 828,660 | Short Ratio: 61.4% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: RVMD — 56.2% short (0.6M / 1.0M)
Short: 561,285 | Exempt: 16,776 | TRF Vol: 998,879 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: RVMD — 60.4% short (0.6M / 1.0M)
Short: 582,429 | Exempt: 9,678 | TRF Vol: 963,968 | Short Ratio: 60.4% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: RVMD — 57.4% short (0.6M / 1.0M)
Short: 557,195 | Exempt: 2,073 | TRF Vol: 970,826 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: RVMD — 57.5% short (0.9M / 1.6M)
Short: 916,112 | Exempt: 2,837 | TRF Vol: 1,594,178 | Short Ratio: 57.5% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: RVMD — 58.1% short (1.8M / 3.1M)
Short: 1,819,630 | Exempt: 18,228 | TRF Vol: 3,132,823 | Short Ratio: 58.1% | Off-exchange volume (dark pool + OTC)
May 31, 2026
fda
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
Results simultaneously published in The New England Journal of Medicine <pre>Results simultaneously published in The New England Journal of Medicine</
May 29, 2026
short_volume
Short Volume: RVMD — 63.0% short (1.4M / 2.2M)
Short: 1,416,665 | Exempt: 5,209 | TRF Vol: 2,248,811 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: RVMD — 57.5% short (0.8M / 1.3M)
Short: 768,951 | Exempt: 11,463 | TRF Vol: 1,338,055 | Short Ratio: 57.5% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: RVMD — 55.2% short (0.4M / 0.7M)
Short: 410,258 | Exempt: 5,638 | TRF Vol: 742,812 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: RVMD — 58.0% short (0.5M / 0.9M)
Short: 525,402 | Exempt: 4,494 | TRF Vol: 905,226 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: RVMD — 63.9% short (0.6M / 0.9M)
Short: 594,783 | Exempt: 2,607 | TRF Vol: 931,427 | Short Ratio: 63.9% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: RVMD — 2.9M shares, 58,124 trades
Week starting 2026-05-18. Total ATS volume: 2,928,860 shares across 58,124 trades.
May 13, 2026
short_volume
Short Volume: RVMD — 58.0% short (0.4M / 0.7M)
Short: 421,633 | Exempt: 3,168 | TRF Vol: 727,303 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_volume
Short Volume: RVMD — 65.8% short (0.4M / 0.5M)
Short: 360,755 | Exempt: 19,094 | TRF Vol: 547,979 | Short Ratio: 65.8% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
Clinical Trial
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Phase Phase 3 — ACTIVE_NOT_RECRUITING